Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03890731 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03890731 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 6 participants.
The verdict
NCT03890731, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how this treatment is tolerated.
Interventions
- DRUG BAY73-4506 (Regorafenib, Stivarga)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-04-02 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03890731
The ClinicalTrials.gov registry entry for NCT03890731 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY73-4506 (Regorafenib, Stivarga) is the first listed.
NCT03890731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03890731 about?
NCT03890731 is a clinical study titled "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed". The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how...
What is the current status of trial NCT03890731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-04-02. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT03890731?
The interventions under investigation include: BAY73-4506 (Regorafenib, Stivarga) (DRUG).
Who is sponsoring clinical trial NCT03890731?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.